PE20212367A1 - Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas - Google Patents

Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Info

Publication number
PE20212367A1
PE20212367A1 PE2021001691A PE2021001691A PE20212367A1 PE 20212367 A1 PE20212367 A1 PE 20212367A1 PE 2021001691 A PE2021001691 A PE 2021001691A PE 2021001691 A PE2021001691 A PE 2021001691A PE 20212367 A1 PE20212367 A1 PE 20212367A1
Authority
PE
Peru
Prior art keywords
solid
plasma concentrations
enhanced performance
achieve therapeutic
therapeutic plasma
Prior art date
Application number
PE2021001691A
Other languages
English (en)
Inventor
Robert J Garmise
Jaquan Kalani Levons
Jay Poorna Reddy
Kevin Stefanski
Vrushali M Waknis
Theresa M Ziemba
Ajay Saxena
Srikanth Koravady Sridhar
Gajendra Singh Chowan
Sharmistha Pal
Shabeerali Pattasseri
Roopa Narasimhamurthy
Narayan Swamy Panduranga
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20212367A1 publication Critical patent/PE20212367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA DISPERSION SOLIDA AMORFA QUE COMPRENDE UN COMPUESTO INHIBIDOR DEL FACTOR XIA (FXIA) DE FORMULA (I) Y UN POLIMERO TAL COMO POLIVINILPIRRROLIDONA (PVP), SUCCINATO DE ACETATO DE HIDROXIPROPILMETILCELULOSA (HPMCAS) Y HIDROXIPROPILMETILCELULOSA (HPMC), EN DONDE LA PROPORCION DEL COMPUESTO (I) A POLIMERO ESTA EN EL INTERVALO DE 99 A 75% (P/P) DEL COMPUESTO (I) Y DE 1 A 25% (P/P) DE POLIMERO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN VEHICULO FARMACEUTICAMENTE ACEPTABLE Y LA DISPERSION SOLIDA AMORFA, EN DONDE LA COMPOSICION ESTA EN FORMA DE UN COMPRIMIDO, CAPSULA O SUSPENSION, LA CUAL ES UTIL EN EL TRATAMIENTO DE UN TRASTORNO TROMBOEMBOLICO.
PE2021001691A 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas PE20212367A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
PE20212367A1 true PE20212367A1 (es) 2021-12-21

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001691A PE20212367A1 (es) 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Country Status (18)

Country Link
US (1) US20220144835A1 (es)
EP (1) EP3953355A1 (es)
JP (1) JP2022526656A (es)
KR (1) KR20210151183A (es)
CN (1) CN113924300A (es)
AR (1) AR118650A1 (es)
AU (1) AU2020271103A1 (es)
BR (1) BR112021020257A2 (es)
CA (1) CA3132530A1 (es)
CL (1) CL2021002627A1 (es)
CO (1) CO2021015054A2 (es)
EA (1) EA202192753A1 (es)
IL (1) IL287103A (es)
MX (1) MX2021012288A (es)
PE (1) PE20212367A1 (es)
SG (1) SG11202111131VA (es)
TW (1) TW202104228A (es)
WO (1) WO2020210629A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232704A1 (en) 2021-03-09 2023-08-31 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
JP2024534427A (ja) 2021-09-17 2024-09-20 ブリストル－マイヤーズ スクイブ カンパニー 血栓塞栓性障害を予防かつ治療するためのミルベキシアン
WO2024030409A1 (en) 2022-08-01 2024-02-08 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
WO2024167899A1 (en) 2023-02-06 2024-08-15 Bristol-Myers Squibb Company Milvexian pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI864812A (fi) 1985-11-27 1987-05-28 Syntex Inc Foerfarande foer framstaellning av amorfa bensimidazolderivat.
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
PE20210470A1 (es) * 2014-01-31 2021-03-08 Bristol Myers Squibb Co Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors

Also Published As

Publication number Publication date
WO2020210629A1 (en) 2020-10-15
AU2020271103A1 (en) 2021-12-02
CL2021002627A1 (es) 2022-05-06
BR112021020257A2 (pt) 2021-12-07
EP3953355A1 (en) 2022-02-16
CO2021015054A2 (es) 2021-11-19
IL287103A (en) 2021-12-01
TW202104228A (zh) 2021-02-01
SG11202111131VA (en) 2021-11-29
EA202192753A1 (ru) 2022-01-11
AR118650A1 (es) 2021-10-20
KR20210151183A (ko) 2021-12-13
US20220144835A1 (en) 2022-05-12
MX2021012288A (es) 2021-11-12
CN113924300A (zh) 2022-01-11
JP2022526656A (ja) 2022-05-25
CA3132530A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
PE20212367A1 (es) Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
CR11724A (es) Agente para tratar enfermedades
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
DOP2009000278A (es) Derivados de bencimidazol
CY1122626T1 (el) Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
MX2019011491A (es) Formulaciones de niraparib.
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
ECSP15051434A (es) Composición farmacéutica de dosis baja
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX341356B (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
PL417879A1 (pl) Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes